公开(公告)号：WO2014062963A1

公开(公告)日：2014-04-24

申请号：PCT/US2013/065514

申请日：2013-10-17

Applicant: AMGEN INC.

Inventor： GAVIN, Marc ,  LIM, Ai Ching

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.

Abstract translation: 本发明提供了与针对IL-21受体的抗原结合蛋白有关的组合物和方法。

公开(公告)号：WO2016164937A3

公开(公告)日：2016-10-13

申请号：PCT/US2016/030843

申请日：2016-05-04

Applicant: AMGEN INC.

Inventor： BUTZ, Eric Alan ,  THOMSON, Christy Ann ,  GAVIN, Marc Alain ,  FOLTZ, Ian Nevin ,  XIA, Dong ,  ALCORN, Dina N. ,  LIM, Ai Ching ,  KETCHEM, Randal Robert ,  MANCHULENKO, Kathy ,  SEKIROV, Laura ,  BERRY, Kelly Ann ,  DE IMUS, Cyr Clovis Chua ,  AGRAWAL, Neeraj Jagdish ,  KANNAN, Gunasekaran ,  LI, Li

IPC: C07K14/55

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：WO2008054603A2

公开(公告)日：2008-05-08

申请号：PCT/US2007/021174

申请日：2007-10-01

Applicant: AMGEN INC. ,  TOCKER, Joel ,  PESCHON, Jacques, J. ,  FITZPATRICK, David ,  SMOTHERS, James, F. ,  MEHLIN, Christopher ,  LIM, Ai Ching

Inventor： TOCKER, Joel ,  PESCHON, Jacques, J. ,  FITZPATRICK, David ,  SMOTHERS, James, F. ,  MEHLIN, Christopher ,  LIM, Ai Ching

IPC: C07K16/00

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.

Abstract translation: 本发明涉及IL-17受体A（IL-17RA或IL-17R）抗原结合蛋白，例如抗体，编码所述抗原结合蛋白的多核苷酸序列，以及用于诊断和治疗由IL-17受体介导的疾病的组合物和方法 一种或多种IL-17配体的活化。 本发明涉及鉴定IL-17受体A（IL-17RA或IL-17R）上的中和决定簇和与之结合的抗体。 本发明的方面还包括与本文所述的IL-17RA中和抗体竞争结合的抗体。

公开(公告)号：WO2007120766A3

公开(公告)日：2007-10-25

申请号：PCT/US2007/009030

申请日：2007-04-13

Applicant: AMGEN INC. ,  BORGES, Luis ,  KETCHEM, Randal R. ,  LIM, Ai Ching ,  MEHLIN, Christopher ,  ZHOU, Hongxing

Inventor： BORGES, Luis ,  KETCHEM, Randal R. ,  LIM, Ai Ching ,  MEHLIN, Christopher ,  ZHOU, Hongxing

IPC: C07K16/28 ,  A61K39/395 ,  A61P7/06

Abstract: Antibodies that bind erythropoeitin receptor are provided. Methods of making and using such antibodies are also provided. Kits containing such antibodies are also provided.

公开(公告)号：WO2016164937A9

公开(公告)日：2016-10-13

申请号：PCT/US2016/030843

申请日：2016-05-04

Applicant: AMGEN INC.

Inventor： BUTZ, Eric Alan ,  THOMSON, Christy Ann ,  GAVIN, Marc Alain ,  FOLTZ, Ian Nevin ,  XIA, Dong ,  ALCORN, Dina N. ,  LIM, Ai Ching ,  KETCHEM, Randal Robert ,  MANCHULENKO, Kathy ,  SEKIROV, Laura ,  BERRY, Kelly Ann ,  DE IMUS, Cyr Clovis Chua ,  AGRAWAL, Neeraj Jagdish ,  KANNAN, Gunasekaran ,  LI, Li

IPC: C07K14/55

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

Abstract translation: 本文提供IL-2突变蛋白，IL-2突变蛋白Fc-融合分子，抗IL-2抗体和包含优先结合IL-2细胞因子的抗IL-2抗体的复合物 扩大并激活T调节细胞，并适合大规模生产。 本文还提供了变体人IgG1Fc分子，其缺乏或具有高度降低的效应子功能和高稳定性，尽管在N297处缺乏糖基化。 本文还提供了在哺乳动物细胞中表达时被糖基化的接头肽。 本文还提供了制备和使用本发明组合物的方法。

公开(公告)号：WO2016164937A2

公开(公告)日：2016-10-13

申请号：PCT/US2016/030843

申请日：2016-05-04

Applicant: AMGEN INC.

Inventor： BUTZ, Eric Alan ,  THOMSON, Christy Ann ,  GAVIN, Marc Alain ,  FOLTZ, Ian Nevin ,  XIA, Dong ,  ALCORN, Dina N. ,  LIM, Ai Ching ,  KETCHEM, Randal Robert ,  MANCHULENKO, Kathy ,  SEKIROV, Laura ,  BERRY, Kelly Ann ,  DE IMUS, Cyr Clovis Chua ,  AGRAWAL, Neeraj Jagdish ,  KANNAN, Gunasekaran ,  LI, Li

IPC: C07K14/55

CPC classification number: C07K14/55 ,  A61K38/00 ,  C07K16/246 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

Abstract translation: 本文提供了IL-2突变蛋白，IL-2突变蛋白Fc-融合分子，抗IL-2抗体和包含与优先扩增和激活T调节细胞的IL-2细胞因子结合的抗IL-2抗体的复合物， 适合大规模生产。 本文还提供了缺乏或具有高度降低的效应子功能和高稳定性的变体人IgG1 Fc分子，尽管在N297缺乏糖基化。 本文还提供了当在哺乳动物细胞中表达时被糖基化的接头肽。 本文还提供了制备和使用本发明组合物的方法。

公开(公告)号：WO2013173761A2

公开(公告)日：2013-11-21

申请号：PCT/US2013/041656

申请日：2013-05-17

Applicant: AMGEN INC.

Inventor： SMITH, Dirk E. ,  FOLTZ, Ian ,  KING, Chadwick T. ,  LIM, Ai Ching ,  CLARK, Rutilio ,  COMEAU, Michael R. ,  KETCHEM, Randal R. ,  SHI, Donghui ,  MIN, Xiaoshan ,  WANG, Zhulun

IPC: C07K16/24 ,  C12N15/11

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/11

Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

Abstract translation: 本文描述的是与抗原结合蛋白相关的组合物和方法，其结合人ST2，包括抗体。 在具体实施方案中，本公开提供完全人抗-ST2抗体及其衍生物和变体。 还提供了编码这种抗体和抗体片段，变体和衍生物的核酸。 此外，提供制备和使用这些抗体的方法，包括治疗和预防自身免疫性和炎症性疾病的方法。